Completed PHASE4 INTERVENTIONAL 2-arm NCT00860938

Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD

Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Cantonal Hosptal, Baselland

Conditions COPD

Interventions Budesonide

Updated 8 times since 2017 Last updated: Jul 22, 2019 Started: Apr 30, 2007 Primary completion: Aug 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on COPD, this trial is completed. The trial is conducted by Cantonal Hosptal, Baselland and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Dec 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Aug 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2017 — Aug 2019 [monthly]

Unknown Status PHASE4

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cantonal Hosptal, Baselland

Data source: Cantonal Hosptal, Baselland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland